Head to head
Viridian Therapeutics vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: VRDN · VRTX
VRDN
Viridian Therapeutics
18.28+0.33%
1-year price shape — -13% over the period
Quant Rating D · 25/100
vs
VRTX
Vertex Pharmaceuticals
505.64+0.66%
1-year price shape — +23% over the period
Quant Rating C · 67/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (67); Vertex Pharmaceuticals has done best over the past year (+23%); Vertex Pharmaceuticals earns the most per share.
| VRDN | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 18.28 | 505.64 |
| Change today | +0.33% | +0.66% |
| 1-year return | -13.0% | +23.2% |
| Market cap | $2.07B | $128.16B |
| 52-week range | 13.18 – 34.29 | 402.58 – 560.25 |
| Valuation | ||
| P/E (TTM) | -5.38 | 29.45 |
| P/E percentile, own 5-yr range | 34th | 74th |
| P/B | 3.67 | 6.33 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -3.32 | 15.32 |
| Net profit (TTM) | $-376.13M | $3.88B |
| Revenue (TTM) | $71.13M | $12.59B |
| Revenue growth (YoY) | +278.7% | +12.5% |
| Gross margin | 23.6% | 86.0% |
| Operating margin | -569.7% | 37.9% |
| Net margin | -544.1% | 35.0% |
| Free cash flow (TTM) | $-335.04M | $3.80B |
| Ownership & sentiment | ||
| Institutional ownership | 119.6% | 97.2% |
| Insider activity (12mo) | 38 buy / 11 sell | 25 buy / 25 sell |
| Short interest (% of float) | 17.2% | 1.9% |
| Analyst consensus | 100% buy (12) | 88% buy / 8% hold / 4% sell (24) |
| Analyst price target | $34 (+87%) | $580 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | D (25) | C (67) |
| Company | ||
| Employees | 252 | 6,400 |
| Founded | 2006 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.